Cytogen Corp says that product sales increased 25% to $2.3 million inthe first quarter of 2001, while its net loss fell to $2.6 million, or $0.03 earnings per share, from $6.1 million, or $0.68 EPS.
Royalty revenue from Quadramet (samarium Sm 153 lexidronam), for the relief of cancer-related bone pain, fell to $441,000 from $498,000 in first-quarter 2000, which the company says was partially due to a temporary, weather-related disruption in the supply of the product from the manufacturer, which has now been resolved. ProstaScint (capromab pendetide), Cytogen's prostate cancer imaging agent, recorded its highest level of quarterly unit sales since launch in 1997, but the actual figure was not revealed. The firm adds that its marketing partner, Schering AG unit Berlex Laboratories, continues to explore expanded uses of Quadramet in combination with other therapies commonly used to treat bone metastases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze